Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A NOVEL HYBRID PROTOCOL FOR RELAPSED GERM CELL TUMOURS
2008-005295-27Phase 2Terminated
- Sponsor
- Barts Health NHS Trust
- Start
- Apr 2009
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of methotrexate, actinomycin D, irinotecan, oxaliplatin and pegfilgrastim, sponsored by Barts Health NHS Trust. Primary endpoint: Tumour response rate to GAMIO. Started Apr 2009; status: terminated.
02
Drugs
methotrexateactinomycin Dirinotecanoxaliplatinpegfilgrastim
Beyond the preview
Go deeper on 2008-005295-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-005295-27.